现金及投资情况 - 公司在2023年12月31日拥有约5.322亿美元的现金、现金等价物和短期投资[311] 投资策略 - 公司的投资目标是在最大化收入的同时保持本金，以降低市场风险[311] 外汇风险 - 公司在欧洲和澳大利亚设立业务，并持有瑞士法郎、欧元和澳大利亚元的现金，面临外汇风险[311]

Krystal Biotech Inc. (NASDAQ:KRYS) Q3 2023 Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants Meg Dodge - VP, Investor Relations & Corporate Communications Krish Krishnan - Chairman & Chief Executive Officer Suma Krishnan - President, Research & Development Kathryn Romano - EVP & Chief Accounting Officer Conference Call Participants Robert Finke - Guggenheim Partners Alec Stranahan - Bank of America Merrill Lynch Ritu Baral - Cowen Carly Kenselaar - Citigroup Dae Gon Ha - Stifel Tim ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ FORM 10-Q _____________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38210 _________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ FORM 10-Q _____________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38210 ______________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ FORM 10-Q _____________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38210 _____________ ...

Developing Genetic Medicines for Rare Diseases Februar y 2023 © Copyright 2023 Krystal Biotech, Inc. All rights reserved. Forward Looking Statements ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________________ FORM 10-K _______________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO ...

DAM Krystal AAD GEM-3 Phase 3 Data Conference Call © Copyright 2022 Krystal Biotech, Inc. All rights reserved. - 1 Forward looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Krystal Biotech, Inc. (the "Company"), including but not limited to statements about the development of the Company's product candidates, such as the future development or commerc ...